Pipeline Zenith Epigenetics Ltd Oncology pipeline. our development strategy is focused on targeting patient subsets with high unmet need and those that are most likely to benefit from therapy. we are advancing multiple clinical programs targeting bet bromodomains in combination with other drugs in oncology indications. our lead product, zen 3694, a bet inhibitor, in. About zenith epigenetics. zenith epigenetics’ experienced research team has developed a cutting edge epigenetic platform, generating differentiated, potent, and selective bet inhibitors. our experienced management team and world leading clinical collaborators are developing beti combination therapies for multiple oncology indications.
Oncology Pipeline Zenithepigenetics Explore zenith epigenetics ltd. with its drug pipeline, therapeutic area, technology platform, 11 clinical trials, 13 news, disease domain:neoplasms, endocrinology and metabolic disease, nervous system diseases, hemic and lymphatic diseases, immune system diseases, infectious diseases, technology platform:small molecule drug, monoclonal antibody, drug:zen 3694, talazoparib tosylate. Calgary, alberta, canada, october 25, 2023, zenith epigenetics ltd. (“zenith” or the “company”), a global leader in epigenetics, announced today it has entered into an agreement with cencora (formerly amerisourcebergen) aimed at accelerating the commercialization of zenith epigenetics’ zen 3694 program. the zen 3694 program is an. About zenith and zen 3694. zenith epigenetics ltd., a wholly owned subsidiary of zenith capital corp., is a clinical stage biotechnology company focused on the discovery and development of novel. About zenith and zen 3694. zenith epigenetics ltd., a wholly owned subsidiary of zenith capital corp., is a clinical stage biotechnology company focused on the discovery and development of novel.
Comments are closed.